The extraordinary fantasy life and lonely death of a New Zealand woman hailed as a heroine after the July 7 bombings in London may be a parable of our celebrity-obsessed times. Or it may be the tragic story of an earnest young woman afflicted by chronic ill health.
However her career is judged, Richmal Oates-Whitehead -- whose body was found 10 days ago in a flat in Shepherd's Bush, west London -- has left behind a confused and contradictory trail over which former friends, colleagues and the medical establishment are still puzzling.
The police appear to have discounted rumors that she committed suicide. The British Medical Association (BMA) on Sunday confirmed that it had held an investigation into how she came to be employed but declined to reveal the outcome.
Oates-Whitehead gained national prominence in her native country thanks to media coverage of the suicide bombing which destroyed the number 30 bus in Tavistock Square outside the headquarters of the BMA. She worked there as editor of Clinical Evidence, an online edition of the British Medical Journal (BMJ). After the blast she appears to have left the building, alongside medically trained staff intent on bringing first aid assistance to survivors.
Precisely what her role was that morning remains uncertain. The 35-year-old always carried a stethoscope in her handbag. She later told the Weekend Herald, a New Zealand newspaper, that she had been helping the injured in a makeshift hospital set up in a hotel next door to the BMA when two firefighters approached her for help. Her account also included a controlled detonation of a second bomb.
But police had no record of a controlled explosion in Tavistock Square; moreover, she was not a doctor. Her name does not appear on either the UK or New Zealand medical council registers.
Coverage of the London bombings triggered suspicions. Intrigued, the Auckland papers began inquiries. On Aug. 15 the New Zealand Herald published a story headlined: "Doctor status of NZ bomb heroine questioned." It disclosed that the BMA was investigating her qualifications. Other papers published similarly skeptical stories.
Their reports unearthed a bizarre pattern. Oates-Whitehead, it emerged, had claimed to be the victim of a stalker, had described herself in some e-mails as a professor, told some friends she had been diagnosed with cancer and informed others she had lost twins born prematurely who lived for only a day.
Challenged by the BMA about her status, she resigned. On Aug. 17, alerted by her concerned family, police went to her flat and found her dead. Initial suspicions focused on the belief that, faced with the humiliation of her exposure and the loss of her job, she might have committed suicide.
But a postmortem report found that she had died of a "pulmonary embolism," or blood clot on the lungs.
In fact, Oates-Whitehead did have a medical background. She trained for a year as a radiation therapist in 1991, which included an internship at Auckland Hospital. She had a postgraduate diploma in health-service management. She also suffered from epilepsy.
She had always dreamed of being a doctor, the New Zealand Sunday Star-Times told its readers. It quoted an interview with a Sydney forensic psychiatrist, Anthony Samuels, who suggested that she may been suffering from borderline personality disorder, and may have posed as a doctor to satisfy a psychological need.
"It is a sad case," he said. "People with borderline personality disorders often get into caring professions because they have so much need themselves and it distracts them from their own pain."
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very